Aranesp extended dosing sBLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen submits an sBLA for use of Aranesp (darbepoetin alfa) every three weeks for chemotherapy-induced anemia in patients with non-myeloid malignancies. Labeling currently recommends a weekly dosing schedule...